TRIUMPH-1 Phase 3 Results: Retatrutide's 28.3% Weight Loss Data Explained

A notable secondary finding concerns the proportion of participants achieving BMI <30 (the threshold defining obesity) and ≥30% weight loss (a level historically associated with bariatric surgery outcomes). At 80 weeks:

• **65.3% of participants on 12 mg retatrutide** achieved BMI <30, including 37.5% of those who began with class 3 obesity (BMI ≥40)
• **45.3% of the 12 mg cohort** achieved ≥30% weight loss
• **37.9% of the 9 mg group** and 15.3% of the 4 mg group achieved ≥30% weight loss

According to [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html), Eli Lilly highlighted that these thresholds reflect outcomes "long associated with bariatric surgery," suggesting retatrutide may offer a pharmacological alternative for patients seeking surgical-level weight reduction without operative intervention.

Extended Follow-Up Data (80–104 Weeks)

A pre-specified blinded extension period allowed participants with baseline BMI ≥35 who completed the 80-week primary trial to continue retatrutide at their maximum tolerated dose (or switch from placebo to active treatment) through week 104. This 24-week extension revealed continued weight loss trajectory:

• Participants continuing retatrutide 12 mg to week 104 achieved **30.3% average body weight reduction (85 lbs average)**
• Weight loss continued to deepen rather than plateau, suggesting sustained pharmacodynamic effect

As [healthline.com](https://www.healthline.com/health-news/eli-lilly-new-drug-retatrutide-shows-greater-weight-loss-results) reported, lead investigator Ania Jastreboff, MD (Yale School of Medicine), noted: "It was remarkable to see this level of weight loss maintained over two years." This extended efficacy window is clinically significant for obesity management, as peptide therapy for weight loss typically requires long-term administration given obesity's chronic nature.

Cardiometabolic Benefit Beyond Weight Loss

Retatrutide demonstrated significant improvements across multiple cardiovascular risk factors from baseline to week 80:

• **Waist circumference**: Significant reduction (specific magnitude reported in trial data)
• **Non-HDL cholesterol**: Clinically meaningful improvement
• **Triglycerides**: Significant reduction
• **Systolic blood pressure**: Measurable decrease
• **High-sensitivity C-reactive protein (hsCRP)**: Reduction indicating decreased systemic inflammation

These secondary endpoints are particularly relevant for researchers evaluating whether retatrutide's triple-agonist mechanism offers advantages over dual GIP/GLP-1 agents. The glucagon component—unique among currently approved weight loss medications—may contribute to improved lipid metabolism and potentially address metabolic dysfunction-associated steatohepatitis (MASH), though dedicated MASH trials remain ongoing.

Safety and Tolerability Profile

The safety data presented a nuanced picture. Discontinuation due to adverse events increased with dose:

• **4 mg retatrutide**: 4.1% discontinuation (lower than placebo's 4.9%)
• **9 mg retatrutide**: Intermediate discontinuation rate
• **12 mg retatrutide**: 11.3% discontinuation versus 4.9% for placebo

Gastrointestinal adverse events were approximately twice as common on the 4 mg dose compared to placebo, though the mechanism underlying this counterintuitive dose-response relationship remains unexplained in available trial summaries. Notably, dysesthesia (a neurological condition) affected 12.5% of patients on the 12 mg dose. According to [fiercebiotech.com](https://www.fiercebiotech.com/biotech/eli-lillys-triple-g-drug-drives-deep-weight-loss-phase-3-obesity-trial), BMO analysts viewed retatrutide's "significantly improved discontinuation rate and rates of dysesthesia" relative to earlier osteoarthritis trial data "as a positive likely to improve uptake when eventually commercialized."

Treatment-Regimen Estimand Results

Beyond the primary efficacy estimand, Lilly also reported results using a treatment-regimen estimand, which included participants who initiated prohibited weight loss treatments. This real-world scenario yielded:

• **4 mg**: 17.6% weight loss
• **9 mg**: 23.7% weight loss
• **12 mg**: 25.0% weight loss
• **Placebo**: 3.9% weight loss

While numerically lower than the efficacy estimand (as expected), these figures remain clinically substantial and may more closely reflect outcomes in routine clinical practice.

Regulatory and Clinical Implications

Based on TRIUMPH-1 data, Lilly has signaled intent to submit retatrutide for FDA approval in 2026. The trial's success establishes retatrutide as a potential game-changer in the obesity pharmaceutical market, though adoption may differ from established agents. Researchers investigating peptide therapy for weight loss will note that retatrutide's triple-agonist approach differentiates it mechanistically from what is a GLP-1 or what is a GIP monotherapy, potentially addressing obesity-related comorbidities more comprehensively.

However, as noted by analysts, the field is increasingly scrutinizing outcomes beyond weight loss alone—specifically lean body mass preservation and bone mineral density effects. Additional Phase 3 data from TRIUMPH-2 (evaluating retatrutide in adults with type 2 diabetes and obesity/overweight) and TRIUMPH-3 (evaluating retatrutide in adults with obesity/overweight and cardiovascular disease) are anticipated later in 2026, which will provide critical insights into metabolic safety and cardiometabolic benefit durability.

Comparative Context

While head-to-head comparisons with currently available medications remain unavailable, TRIUMPH-1 results position retatrutide's efficacy above most published dual-agonist trials. Researchers evaluating what is semaglutide or what is a GLP-1 impact on consumer spending and clinical adoption should consider that retatrutide's 28.3% weight loss at 12 mg exceeds typical semaglutide efficacy in comparable populations, potentially reshaping treatment hierarchies in obesity management.

Research Considerations and Limitations

The TRIUMPH-1 trial enrolled participants without type 2 diabetes, limiting direct generalizability to diabetic obesity populations—though TRIUMPH-2 will address this gap. The efficacy estimand, while scientifically rigorous, excludes participants who added other weight loss treatments, potentially overestimating real-world efficacy. Long-term safety data beyond 104 weeks remain unavailable, as does direct comparative efficacy data against established GLP-1 or dual GIP/GLP-1 agents.

Conclusion

The TRIUMPH-1 Phase 3 trial establishes retatrutide as a pharmacologically distinct triple-agonist with efficacy exceeding current standard-of-care weight loss medications. The 28.3% weight loss achieved at 12 mg, coupled with sustained benefit through 104 weeks and meaningful cardiometabolic improvements, represents a significant advancement in obesity pharmacotherapy. Researchers and clinicians should anticipate additional Phase 3 data in late 2026 to fully characterize retatrutide's role in obesity and related metabolic disorders.